Deployment Health Research Department, Naval Health Research Center, San Diego, California.
Obstet Gynecol. 2013 Mar;121(3):511-518. doi: 10.1097/AOG.0b013e318280d64e.
To assess adverse pregnancy outcomes among active-duty U.S. military women who received pandemic H1N1 vaccine during pregnancy as well as adverse health outcomes among the newborns resulting from these pregnancies.
The primary study population was a retrospective cohort of active-duty U.S. military women vaccinated during pregnancy with either the pandemic H1N1 vaccine between October 2009 and June 2010 or with seasonal influenza vaccine between October 2008 and June 2009. Rates of pregnancy loss, preeclampsia or eclampsia, and preterm labor were compared between pandemic H1N1 vaccine-exposed (n=10,376) and seasonal influenza vaccine-exposed pregnancies (n=7,560). A secondary study population consisted of newborns resulting from these pregnancies. Rates of preterm birth, birth defects, fetal growth problems, and the male-to-female sex ratio were compared between newborns exposed to pandemic H1N1 vaccine and newborns exposed to seasonal influenza vaccine in utero.
No significant differences were observed in rates of pregnancy loss (6.4% compared with 6.5%), preeclampsia or eclampsia (5.8% compared with 5.2%), or preterm labor (6.5% compared with 6.2%) between pandemic H1N1 vaccine-exposed and seasonal influenza vaccine-exposed pregnancies. Furthermore, no significant differences were observed in rates of preterm birth (6.2% compared with 6.3%), birth defects (2.1% compared with 2.0%), fetal growth problems (2.6% compared with 2.4%), or the male-to-female sex ratio (1.05 compared with 1.07) between newborns exposed in utero to pandemic H1N1 vaccine compared with seasonal influenza vaccine. Rates of all outcomes were lower or similar to overall general population rates. This study had at least 80% power to detect hazard ratios of 1.18-1.21 or odds ratios of 1.10-1.36, depending on outcome prevalence.
No adverse pregnancy or newborn health outcomes associated with pandemic H1N1 vaccination during pregnancy were noted among our cohort. These findings should be used to encourage increased vaccine coverage among pregnant women.
评估在怀孕期间接种大流行性 H1N1 疫苗的现役美国女性的不良妊娠结局,以及由此导致的新生儿不良健康结局。
主要研究人群为在怀孕期间接种大流行性 H1N1 疫苗(2009 年 10 月至 2010 年 6 月)或季节性流感疫苗(2008 年 10 月至 2009 年 6 月)的现役美国女性的回顾性队列。比较大流行性 H1N1 疫苗暴露组(n=10376)和季节性流感疫苗暴露组(n=7560)的妊娠丢失、子痫前期或子痫以及早产的发生率。次要研究人群由这些妊娠产生的新生儿组成。比较暴露于大流行性 H1N1 疫苗和暴露于季节性流感疫苗的新生儿的早产、出生缺陷、胎儿生长问题和男性与女性的性别比例。
大流行性 H1N1 疫苗暴露组与季节性流感疫苗暴露组的妊娠丢失率(6.4%比 6.5%)、子痫前期或子痫发生率(5.8%比 5.2%)或早产发生率(6.5%比 6.2%)无显著差异。此外,暴露于大流行性 H1N1 疫苗的新生儿与暴露于季节性流感疫苗的新生儿的早产率(6.2%比 6.3%)、出生缺陷率(2.1%比 2.0%)、胎儿生长问题率(2.6%比 2.4%)或男性与女性的性别比例(1.05 比 1.07)无显著差异。所有结局的发生率均低于或与一般人群的总体发生率相似。本研究具有至少 80%的效力,可检测到与怀孕期间接种大流行性 H1N1 疫苗相关的危害比为 1.18-1.21 或优势比为 1.10-1.36,具体取决于结局的发生率。
在我们的队列中,没有发现与怀孕期间接种大流行性 H1N1 疫苗相关的不良妊娠或新生儿健康结局。这些发现应该用于鼓励增加孕妇的疫苗接种率。